VALNEVA SE SP.ADS/2 Market Cap ($474.12 Million)
Market Cap & Net Worth: VALNEVA SE SP.ADS/2 (AYJ0)
VALNEVA SE SP.ADS/2 market cap. VALNEVA SE SP.ADS/2 (F:AYJ0) has a market capitalization of $474.12 Million (€405.54 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #12204 globally and #1336 in its home market, demonstrating a -3.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VALNEVA SE SP.ADS/2's stock price €4.58 by its total outstanding shares 94823458 (94.82 Million). Also see how efficiently does VALNEVA SE SP.ADS/2 generate cash for how efficiently the company converts equity into cash flow.
VALNEVA SE SP.ADS/2 Market Cap History (2021–2026)
VALNEVA SE SP.ADS/2 market cap history from 2021 to 2026. Data shows change from $5.48 Billion to $507.73 Million (-26.27% CAGR). Check latest VALNEVA SE SP.ADS/2 stock price today for real-time trading data and today's change.
VALNEVA SE SP.ADS/2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VALNEVA SE SP.ADS/2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore VALNEVA SE SP.ADS/2 (AYJ0) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.63x
VALNEVA SE SP.ADS/2's market cap is 4.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $5.48 Billion | $348.08 Million | -$73.42 Million | 15.73x | N/A |
| 2022 | $1.37 Billion | $361.30 Million | -$143.28 Million | 3.79x | N/A |
| 2023 | $1.01 Billion | $153.71 Million | -$101.43 Million | 6.56x | N/A |
| 2024 | $487.78 Million | $169.58 Million | -$12.25 Million | 2.88x | N/A |
| 2025 | $809.27 Million | $174.66 Million | -$115.19 Million | 4.63x | N/A |
Competitor Companies of AYJ0 by Market Capitalization
Companies near VALNEVA SE SP.ADS/2 in the global market cap rankings as of November 4, 2026. Also see AYJ0 total assets for a full breakdown of the balance sheet.
Key companies related to VALNEVA SE SP.ADS/2 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of VALNEVA SE SP.ADS/2 (2021–2026)
Market capitalization of VALNEVA SE SP.ADS/2 from 2021 to today. Between 2021 and today, VALNEVA SE SP.ADS/2's market cap moved from $5.48 Billion to $ 507.73 Million, with a yearly change of -26.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €507.73 Million | -37.26% |
| 2025 | €809.27 Million | +65.91% |
| 2024 | €487.78 Million | -51.65% |
| 2023 | €1.01 Billion | -26.32% |
| 2022 | €1.37 Billion | -75.00% |
| 2021 | €5.48 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of VALNEVA SE SP.ADS/2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $474.12 Million USD |
| MoneyControl | $474.12 Million USD |
| MarketWatch | $474.12 Million USD |
| marketcap.company | $474.12 Million USD |
| Reuters | $474.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About VALNEVA SE SP.ADS/2
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more